Cosmetics — including peptide-infused setting sprays — do not require FDA pre-market approval in the United States. However, they are subject to the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which introduced several new mandatory requirements that took effect in stages through 2023 and 2024 and that brands and their manufacturers must now comply with.
Under MoCRA, every cosmetic manufacturing or processing facility must register with the FDA (facility registration opened December 29, 2023, and was required by July 1, 2024, for domestic facilities). Every cosmetic product must also be listed with the FDA through the Cosmetics Direct electronic portal, including its ingredient list. This applies to brands, not just manufacturers — so even if your contract manufacturer's facility is already registered, your brand must complete a separate product listing for each SKU.
The FDA also now requires that manufacturers maintain records substantiating safety for each cosmetic product and that they report serious adverse events to the FDA within 15 days. Your private label agreement should specify which party (brand or manufacturer) holds the safety substantiation file, because you will be responsible for producing it if the FDA requests it.
For a peptide setting spray specifically, no ingredient in the most common peptide actives (Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7, Acetyl Hexapeptide-3, GHK-Cu) appears on the FDA's restricted or prohibited ingredient list or on California's Prop 65 list at typical use concentrations. That said, if you are making drug-like claims — "clinically proven to reduce wrinkles" — rather than cosmetic claims — "visibly improves the appearance of fine lines" — the product may be regulated as an OTC drug, which does require FDA approval of a new drug application. Keep claims cosmetic.
For brands selling into the EU, the EU Cosmetics Regulation (EC No 1223/2009) requires notification through the Cosmetic Products Notification Portal (CPNP) before market entry, a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor, and a Responsible Person established within the EU. Most EU-experienced contract manufacturers can facilitate the CPSR; allow 4–8 additional weeks and $1,500–$3,000 in cost for this documentation.
UK post-Brexit requires a separate UK Responsible Person and SCPN notification. Canada requires notification to Health Canada under the Cosmetic Regulations if the product contains certain ingredients above defined thresholds.
AJ Cosmo Labs can connect you with manufacturers who are already MoCRA-compliant and who offer regulatory documentation support as part of their private label program — post your brief in the iOS app and specify your target markets.
Read the full guide on Private Label Peptide Setting Spray Manufacturer Low MOQ →